A look in­to the 340B ex­plo­sion of growth as Gilead and J&J join more than a dozen peers set­ting their own terms

As a new re­port doc­u­ments the ex­plo­sive growth of a fed­er­al pro­gram pro­vid­ing dis­count­ed drugs for low-in­come Amer­i­cans, two more large phar­ma com­pa­nies — Gilead and John­son & John­son — will place new re­stric­tions around their poli­cies for the pro­gram, known as 340B.

In­clud­ing Gilead and J&J, a to­tal of 16 phar­ma com­pa­nies have now re­worked their 340B op­er­a­tions over the last sev­er­al years as law­suits have sought to con­strain the firms from what they see as a bal­loon­ing por­tion of the US pre­scrip­tion drug mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.